ABBVIE INC (4AB.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:4AB - US00287Y1091 - Common Stock
181.8 EUR
-1.4 (-0.76%)
Overall 4AB gets a fundamental rating of 5 out of 10. We evaluated 4AB against 86 industry peers in the Biotechnology industry. While 4AB is still in line with the averages on profitability rating, there are concerns on its financial health. 4AB is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year 4AB was profitable.
- 4AB had a positive operating cash flow in the past year.
- Each year in the past 5 years 4AB has been profitable.
- In the past 5 years 4AB always reported a positive cash flow from operatings.
1.2 Ratios
- 4AB has a Return On Assets of 1.75%. This is in the better half of the industry: 4AB outperforms 75.58% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 15.64%, 4AB belongs to the top of the industry, outperforming 94.19% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for 4AB is above the industry average of 11.58%.
- The 3 year average ROIC (13.67%) for 4AB is below the current ROIC(15.64%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROIC | 15.64% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
1.3 Margins
- 4AB's Profit Margin of 3.94% is fine compared to the rest of the industry. 4AB outperforms 77.91% of its industry peers.
- 4AB's Profit Margin has declined in the last couple of years.
- 4AB's Operating Margin of 33.05% is amongst the best of the industry. 4AB outperforms 89.53% of its industry peers.
- In the last couple of years the Operating Margin of 4AB has declined.
- The Gross Margin of 4AB (71.16%) is better than 62.79% of its industry peers.
- In the last couple of years the Gross Margin of 4AB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% |
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 4AB is creating value.
- Compared to 1 year ago, 4AB has about the same amount of shares outstanding.
- 4AB has more shares outstanding than it did 5 years ago.
- 4AB has a worse debt/assets ratio than last year.
2.2 Solvency
- 4AB has an Altman-Z score of 2.34. This is not the best score and indicates that 4AB is in the grey zone with still only limited risk for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 2.34, 4AB is in the better half of the industry, outperforming 69.77% of the companies in the same industry.
- 4AB has a debt to FCF ratio of 3.49. This is a good value and a sign of high solvency as 4AB would need 3.49 years to pay back of all of its debts.
- The Debt to FCF ratio of 4AB (3.49) is better than 82.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Altman-Z | 2.34 |
ROIC/WACC1.85
WACC8.43%
2.3 Liquidity
- A Current Ratio of 0.72 indicates that 4AB may have some problems paying its short term obligations.
- The Current ratio of 4AB (0.72) is worse than 76.74% of its industry peers.
- A Quick Ratio of 0.60 indicates that 4AB may have some problems paying its short term obligations.
- 4AB has a worse Quick ratio (0.60) than 76.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 |
3. Growth
3.1 Past
- 4AB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.09%.
- 4AB shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.51% yearly.
- The Revenue has been growing slightly by 7.40% in the past year.
- 4AB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.11% yearly.
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
3.2 Future
- 4AB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.67% yearly.
- Based on estimates for the next years, 4AB will show a small growth in Revenue. The Revenue will grow by 7.50% on average per year.
EPS Next Y7.3%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
EPS Next 5Y13.67%
Revenue Next Year8.74%
Revenue Next 2Y9.15%
Revenue Next 3Y8.74%
Revenue Next 5Y7.5%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- 4AB is valuated rather expensively with a Price/Earnings ratio of 22.39.
- 4AB's Price/Earnings ratio is rather cheap when compared to the industry. 4AB is cheaper than 82.56% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.38, 4AB is valued at the same level.
- With a Price/Forward Earnings ratio of 14.55, 4AB is valued correctly.
- Based on the Price/Forward Earnings ratio, 4AB is valued cheaply inside the industry as 89.53% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.29, 4AB is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.39 | ||
| Fwd PE | 14.55 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 4AB indicates a somewhat cheap valuation: 4AB is cheaper than 79.07% of the companies listed in the same industry.
- 86.05% of the companies in the same industry are more expensive than 4AB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.99 | ||
| EV/EBITDA | 15.58 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The decent profitability rating of 4AB may justify a higher PE ratio.
- 4AB's earnings are expected to grow with 16.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.07
PEG (5Y)8.92
EPS Next 2Y19.85%
EPS Next 3Y16.87%
5. Dividend
5.1 Amount
- 4AB has a Yearly Dividend Yield of 3.19%. Purely for dividend investing, there may be better candidates out there.
- Compared to an average industry Dividend Yield of 0.75, 4AB pays a better dividend. On top of this 4AB pays more dividend than 96.51% of the companies listed in the same industry.
- 4AB's Dividend Yield is rather good when compared to the S&P500 average which is at 1.84.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.19% |
5.2 History
- On average, the dividend of 4AB grows each year by 7.72%, which is quite nice.
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
- 4AB pays out 489.69% of its income as dividend. This is not a sustainable payout ratio.
- The dividend of 4AB is growing, but earnings are growing more, so the dividend growth is sustainable.
DP489.69%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
FRA:4AB (1/20/2026, 5:28:00 PM)
181.8
-1.4 (-0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2025-10-31/bmo
Earnings (Next)02-04 2026-02-04/amc
Inst Owners75.04%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap321.31B
Revenue(TTM)59.64B
Net Income(TTM)2.35B
Analysts78.38
Price Target213.08 (17.21%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.19% |
Yearly Dividend5.38
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)-0.08%
PT rev (3m)8.41%
EPS NQ rev (1m)-3.35%
EPS NQ rev (3m)-2.56%
EPS NY rev (1m)0.02%
EPS NY rev (3m)-11.46%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)0.48%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.39 | ||
| Fwd PE | 14.55 | ||
| P/S | 6.27 | ||
| P/FCF | 18.99 | ||
| P/OCF | 17.92 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.58 |
EPS(TTM)8.12
EY4.47%
EPS(NY)12.5
Fwd EY6.87%
FCF(TTM)9.58
FCFY5.27%
OCF(TTM)10.15
OCFY5.58%
SpS29.01
BVpS-1.29
TBVpS-45.04
PEG (NY)3.07
PEG (5Y)8.92
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROCE | 20.86% | ||
| ROIC | 15.64% | ||
| ROICexc | 16.59% | ||
| ROICexgc | 572.43% | ||
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% | ||
| FCFM | 33% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 14.25% | ||
| Cap/Sales | 1.97% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 838.33% | ||
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 | ||
| Altman-Z | 2.34 |
F-Score7
WACC8.43%
ROIC/WACC1.85
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
EPS Next Y7.3%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
EPS Next 5Y13.67%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
Revenue Next Year8.74%
Revenue Next 2Y9.15%
Revenue Next 3Y8.74%
Revenue Next 5Y7.5%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year9.3%
EBIT Next 3Y15.61%
EBIT Next 5Y10.95%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%
ABBVIE INC / 4AB.DE FAQ
What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.
What is the valuation status for 4AB stock?
ChartMill assigns a valuation rating of 6 / 10 to ABBVIE INC (4AB.DE). This can be considered as Fairly Valued.
How profitable is ABBVIE INC (4AB.DE) stock?
ABBVIE INC (4AB.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for 4AB stock?
The financial health rating of ABBVIE INC (4AB.DE) is 3 / 10.
How sustainable is the dividend of ABBVIE INC (4AB.DE) stock?
The dividend rating of ABBVIE INC (4AB.DE) is 6 / 10 and the dividend payout ratio is 489.69%.